Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan

Takeshi Arashiro

; YuzoArima; JinKuramochi; HirokazuMuraoka; AkihiroSato; KumiChubachi; AtsushiYanai; HirokoArioka; YukiUehara; GeneiIhara; +22 more... YasuyukiKato; NaokiYanagisawa; AkihiroUeda; Hideaki Kato

; HideakiOka; YusukeNishida; YukiNidaira; Takahiro Asami

; TorahikoJinta; AkiraNakamura; KunihiroOba; DaisukeTaniyama; KeiYamamoto; KatsushiTanaka; KankuroUeshima; TetsujiFuwa; AshleyStucky; TadakiSuzuki; Chris Smith

; MartinHibberd; Koya Ariyoshi

; MotoiSuzuki; (2023) Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan. Open forum infectious diseases. ISSN 2328-8957 DOI: 10.1093/ofid/ofad240

Copy

In this multi-center prospective test-negative case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65% and 76%) and moderate compared to monovalent vaccines administered over half a year before (46% combined).

Item Type	Article
Elements ID	202550
Official URL	http://dx.doi.org/10.1093/ofid/ofad240

Atom

BibTeX

OpenURL ContextObject in Span

Multiline CSV

OpenURL ContextObject

Dublin Core

MPEG-21 DIDL

EndNote

HTML Citation

JSON

MARC (ASCII)

MARC (ISO 2709)

METS

MODS

RDF+N3

RDF+N-Triples

RDF+XML

RIOXX2 XML

Reference Manager

Refer

Simple Metadata

ASCII Citation

EP3 XML

Export

Downloads

picture_as_pdf: Arashiro-etal-2023-effectiveness-of-BA1.pdf
subject: Published Version
: Available under Creative Commons: NC-ND 3.0

View

Download

Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan

Explore Further